Anthony D. Piscopio, Ph.D.

Chief Executive Officer & President

Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation.

Prior to this, Dr. Piscopio co-founded Array BioPharma (ARRY;NASDAQ) where he served as V.P. of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale and oncology drug discovery. Prior to founding Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division, Boulder, CO, and served as a research scientist at Pfizer. Dr. Piscopio was an NIH Postdoctoral Fellow at The Scripps Research Institute and received his Ph.D. at the University of Wisconsin-Madison.

John DeMattei, Ph.D.

Chief Operating Officer & Senior Vice President of Chemistry

Dr. DeMattei is a pharmaceutical development expert with experience in the development of small molecule and oligonucleotide therapeutics. During his pharmaceutical development career, Dr. DeMattei has provided leadership to pharmaceutical development teams that have contributed to more than 25 INDs, 3 approved NDAs, and 1 approved BLA. Prior to joining OnKure, Dr. DeMattei served as the Sr. Director of Oligonucleotide Technology at Dynavax Inc. Dr. DeMattei received his academic training in chemistry at the University of Illinois, UCLA, and Harvard; and he has contributed to more than 30 issued patents and publications.

Jim Winkler, Ph.D.

Chief Scientific Officer

Jim Winkler is Chief Scientific Officer, working with the OnKure Team and its collaborators to match OnKure’s unique drugs to the right patient populations. Dr. Winkler has spent close to 40 years in the field of drug discovery and development, working at companies of varying size: Johnson & Johnson, SmithKline Beecham, GlaxoSmithKline, Array BioPharma, Arvinas and FORMA Therapeutics. While working for these companies, he gained extensive experience building and leading teams, working from target validation and early drug discovery through to translational medicine and clinical development.

Dr. Winkler joined Arvinas as the CSO, helping the new company focus on a novel technology, targeted protein degradation. Dr. Winkler and the team helped build the company, validate and further advance this technology, and built a growing preclinical pipeline of degraders, enabling Arvinas to go public. At Array, Dr. Winkler was the VP of Biology, leading a discovery and early development organization with an impressive record of accomplishment, moving over 16 drugs into the clinic, several of which have moved to Phase 3 and registration.

Dr. Winkler has significant experience in Oncology and Inflammatory diseases, as well as proficiency in supervision, business development and collaboration management. He did his postdoctoral training with Dr. Stanley Crooke at SmithKline Beecham and received his Ph.D. in Pharmacology at the Medical College of Pennsylvania.

Keith Olivia

General Counsel, Senior
Vice President of Corporate Affairs & Secretary

Keith M. Olivia has served as General Counsel and Vice President of Corporate Affairs of OnKure since April 2019. Prior to joining OnKure, Mr. Olivia practiced transactional law with international, regional and boutique business law firms in Boulder and Denver, Colorado since 1997, including serving as OnKure’s corporate counsel since its founding in April 2011. He has also taught as an adjunct faculty member at the University of Colorado School of Law’s Entrepreneurial Law Clinic and an adjunct faculty member at the Colorado State University’s Global Social and Sustainable Enterprise MBA Program.

Mr. Olivia received a B.S. in Finance with a Minor in Economics from the Pennsylvania State University, Smeal College of Business; a J.D. with honors from The Ohio State University, Moritz College of Law; and an LL.M. in Taxation from the University of Florida, Fredric G. Levin College of Law. He has been admitted to practice law in the State of Colorado since 1995.


Isaac Manke, Ph.D.


Isaac is a General Partner at Acorn BioVentures. Previously, he was a General Partner at New Leaf Venture Partners, where he invested across private and public biotechnology companies for 11 years. Prior to his venture capital career, he was an Associate equity analyst in the Global Biotechnology Equity Research group at Sanford C. Bernstein and prior to that in the Biotechnology Equity Research group at Deutsche Bank. Prior these roles he was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm.

Isaac received a Ph.D. in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology (MIT) and a B.A. in Biology and B.A. in Chemistry at Minnesota State University (Moorhead). During his research career Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of the “2003: Signaling Breakthroughs of the Year”. These discoveries also resulted in four issued patents.

Anthony D. Piscopio, Ph.D.


Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation.

R. Michael Carruthers


Michael Carruthers currently serves as the Chief Financial Officer of Edgewise Therapeutics (NASDAQ: EWTX). Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly traded company acquired by Alpine Immune Sciences, in 2017 and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation and Accountant with Coopers & Lybrand. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Andrew Phillips, Ph.D.


Andy Phillips, Ph. D. is a Managing Director at Cormorant Asset Management, LP (“Cormorant”). Before joining Cormorant, Andy was the President and Chief Executive Officer of C4 Therapeutics. Prior to joining C4 Therapeutics, Andy was Senior Director, Center for Development of Therapeutics at the Broad Institute of MIT and Harvard. Previously, he was a Professor of Chemistry at Yale University and a Professor of Chemistry and Biochemistry at the University of Colorado. Andy holds Ph.D. and B.Sc. Hons. degrees in Biochemistry and Chemistry from the University of Canterbury (Christchurch, New Zealand).

Guabao Zhao


Guobao Zhao joined Delian Capital in 2015 as Venture Partner. He is also senior vice president of Chance Pharmaceuticals, a Delian Portfolio company focused on the development of novel inhaled treatments of pulmonary diseases. Before joining Delian Capital, Mr. Zhao served as R&D Manager at CASI Pharmaceuticals (NASDAQ: CASI). Prior to CASI Pharmaceuticals, Mr. Zhao served as a Research Scientist at PPD. Mr. Zhao has led Delian’s investments in Amunix, Apexigen, MicuRx. In addition, Mr.Zhao also represents Delian as a Board member or observer on OnKure, Hummingbird Bioscience, and Chance Pharmaceuticals. Mr. Zhao received his B.S. in Pharmacy from Huazhong University of Science and Technology, and his M.S. in Medicinal Chemistry from AMMI and MBA from China Agricultural University.

Kevin Koch, Ph.D.

Scientific Advisor

Dr. Kevin Koch, Ph.D. has served as the President and Chief Executive Officer of Edgewise Therapeutics since July 2017 and a Venture Partner at OrbiMed Advisors, LLC since May 2016. Dr. Koch has been active in the life science industry for 25+ years with a focus on drug discovery, translational medicine and clinical development. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to joining Biogen, Dr. Koch was a Co-Founder of Array Biopharma Inc. and served as its President, Chief Scientific Officer and Director from May 1998 to November 2013. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in the multiple therapeutic areas. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Prior to in Array, Dr. Koch served as an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to April 1998 for Amgen Inc. From September 1988 to May 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator, Senior Research Scientist, and Project Coordinator for the Cellular Migration and Immunology Project Teams. Prior to acting as a consultant, Dr. Koch served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, Inc. from December 2013 to September 2015, where he managed global drug discovery and biomarker development as well as the immunology and hematology teams. Dr. Koch is the Treasurer and Board Member of the Inflammation Research Association. Dr. Koch has been a Director of miRagen Therapeutics, Inc. since February 2017. Prior to joining miRagen Therapeutics Board, he served as a Member of Private Miragen’s Board of Directors since July 2016. He is a Founding Board Member of Skyhawk Therapeutics, Inc. Dr. Koch serves on the boards of Neurogastrx, Inc. and Encycle Therapeutics and consults with several life science companies. Dr. Koch served as a Director of Array Biopharma, Inc. from May 1998 to October 24, 2012. He is a Director of Skyhawk Therapeutics, Inc. He is a co-author or inventor of multiple patents and publications. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York in 1983, Stony Brook and his Ph.D. in Synthetic Organic Chemistry from University of Rochester in 1988 and M.S in organic chemistry from University of Rochester in 1986.

Lia Gore, M.D.

Scientific Advisor

Dr. Gore joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2001. She trained in Pediatrics at Children’s National Medical Center and the University of Colorado. She completed her fellowship training in pediatric hematology/oncology/bone marrow transplantation at the University of Colorado Cancer Center and Children’s Hospital Colorado.

Dr. Gore is a member of the Developmental Therapeutics (phase I clinical trials) Program, where she also directs the Early Phase Hematological Malignancies Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. She is the founder and the Program Leader of the Experimental Therapeutics Program at Children’s Hospital Colorado.

She co-founded and co-directs the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) and collaborates regularly with European Investigators on international phase I oncology studies. Dr. Gore’s primary interests are in leukemias and sarcomas. She has received funding from the National Cancer Institute, the Leukemia and Lymphoma Society, Alex’s Lemonade Stand, and numerous foundation awards. She has more than 65 publications of her work and has lectured extensively nationally and internationally.

Pamela Munster, M.D.

Scientific Advisor

Dr. Munster’s clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. Pam has been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, her main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer. Her basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, Dr. Munster has shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

Xuedong Liu, Ph.D.

Scientific Advisor

Xuedong Liu is a Professor of Chemistry and Biochemistry at the University of Colorado-Boulder. He received his Ph.D. in Genetics from the University of Wisconsin-Madison in 1994 with Professor Janet Mertz at McArdle Laboratory for Cancer Research. From 1995 to 2000, he was an NIH and DOD postdoctoral fellow at the Whitehead Institute for Biomedical Research with Professor Harvey F. Lodish at Massachusetts Institute of Technology. He has been on faculty of the University of Colorado-Boulder since 2000.
Professor Liu’s research interests include the biochemistry and systems biology of cell signaling. He focuses on understanding signal transduction mechanism of growth factors and small molecule ligands in normal and cancer cells. His laboratory also works on deciphering molecular mechanisms of neurodegenerative disorders such as Parkinson’s disease. Professor Liu has authored or co-authored more than 75 research papers and patents and is the coeditor of a book entitled “Computational Modeling of Signaling Networks”. In addition, Professsor Liu is an OnKure co-founder and is responsible for the developing the profile-specific histone deacetylase inhibitor platform which forms the basis of OnKure’s technology. Professor Liu is the recipient of Inventor of the Year Award in 2013 from the University of Colorado.